Middle East and Africa Cancer Targeted Therapy Market Report Outlook (2021–2031)

Breakthroughs in Genomic Profiling and Biomarker Studies

Advancements in genomic profiling and biomarker discovery are the primary market drivers. With rising cancer incidence across the region, clinicians are increasingly moving away from conventional chemotherapy toward precision medicine approaches that tailor treatment to a patient's unique tumor profile. Molecular diagnostics—such as next-generation sequencing, whole-exome sequencing, and liquid biopsy technologies—allow the detection of actionable genetic alterations, including EGFR, HER2, ALK, and PIK3CA mutations. These alterations directly inform therapy selection, leading to higher efficacy, reduced systemic toxicity, and improved patient outcomes.

Companion diagnostics—now being integrated into clinical workflows in advanced oncology centers in Saudi Arabia, the UAE, South Africa, and Egypt—support better patient stratification for targeted agents. The growing availability of hospital-based genomic testing labs and collaborations between global pharmaceutical companies and local institutions have made biomarker-driven therapies more accessible. Liquid biopsies—which detect circulating tumor DNA—are becoming increasingly adopted for monitoring treatment response, identifying minimal residual disease, detecting early therapy resistance, extending therapy duration, and improving quality of life.

Additionally, the accumulation of real-world genomic data and regional research collaborations supports the identification of novel biomarkers, enabling earlier adoption of targeted agents. Government initiatives to enhance diagnostic infrastructure, coupled with reimbursement support in select countries, further fuel adoption. Overall, the integration of genomic profiling and biomarker discovery has become a critical enabler of targeted therapy growth, driving improvements in clinical outcomes and expanding market opportunities.

Mutation-Guided Therapies for Rare Cancers and Tumors

The expansion of targeted therapies into rare cancers and tumors with specific genetic mutations presents a significant opportunity. Historically, rare cancers have been underserved due to small patient populations, high development costs, and limited commercial potential. However, advances in genomic profiling have revealed that many rare tumors share actionable genetic alterations across multiple cancer types, creating an opportunity for tumor-agnostic therapies. Agents targeting NTRK fusions, RET rearrangements, and BRAF mutations now allow a single drug to be applied to multiple rare malignancies, enhancing the commercial viability of these therapies.

Clinical adoption is being facilitated by next-generation sequencing and comprehensive molecular testing, which enable early detection of rare mutations in patients, even in urban oncology centers with advanced diagnostic infrastructure. Innovative trial designs—such as basket and umbrella trials—have reduced development timelines and costs, allowing pharmaceutical companies to bring therapies to market faster. Regulatory frameworks, influenced by global standards, are increasingly supportive of orphan drug approvals and accelerated pathways for targeted agents in rare cancers.

Furthermore, multinational pharmaceutical companies are leveraging partnerships with local distributors, private hospitals, and government programs to expand market access. Patient assistance programs, training for clinicians, and inclusion in regional clinical trial networks enhance adoption in both common and rare cancer populations. As a result, the rare cancer segment not only addresses a previously unmet clinical need but also opens new revenue streams and strengthens development pipelines, positioning the region as a strategic growth market for precision oncology therapies.

The "Middle East and Africa Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Middle East and Africa Cancer Targeted Therapy market size and forecast at regional and country levels for key segments covered under the scope
• Middle East and Africa Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Middle East and Africa Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Middle East and Africa Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Middle East and Africa Cancer Targeted Therapy market report is divided into: Turkiye, the UAE, Saudi Arabia, Bahrain, Oman, Egypt, South Africa and Africa, Algeria, Nigeria, Kuwait, and Qatar. South Africa held the largest share in 2024.

The Middle East and Africa (MEA) cancer targeted therapy market exhibits diverse adoption patterns driven by differences in healthcare infrastructure, regulatory support, and public-private investment. Saudi Arabia and the UAE lead the region due to advanced healthcare systems, early adoption of precision medicine, and significant government support for oncology care. Modern oncology centers in these countries are equipped with molecular diagnostics, infusion facilities, and trained specialists, allowing broader use of targeted therapies, particularly monoclonal antibodies and tyrosine kinase inhibitors. Reimbursement frameworks and national cancer control programs further facilitate patient access to high-cost therapies. South Africa represents a mature oncology market within sub-Saharan Africa, characterized by well-developed hospital infrastructure, access to a wide range of targeted therapies, and participation in global clinical trials. Urban hospitals offer comprehensive care—including molecular testing, therapy monitoring, and combination regimens—driving adoption of targeted agents for lung, breast, and colorectal cancers.

Private hospitals and specialty oncology clinics supplement public facilities, ensuring broader distribution of advanced therapies. Egypt and North African countries—including Algeria—are experiencing incremental growth due to government initiatives to modernize tertiary hospitals, expand diagnostic capacity, and train oncologists. Urban centers show higher uptake of targeted therapies, while rural regions still face challenges related to affordability, infrastructure, and diagnostic access. Across the region, hospital pharmacies remain the dominant distribution channel due to the clinical administration requirements of biologics, while retail and specialty pharmacies handle oral targeted drugs. Multinational pharmaceutical companies continue to strengthen their presence through partnerships, biosimilar launches, and educational programs for clinicians. Collectively, these country-level dynamics highlight a patchwork of opportunities that require localized strategies, with premium adoption in GCC countries, affordability focus in African markets, and partnership-driven expansion in emerging economies.

• The report includes qualitative and quantitative data in the Middle East and Africa Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the Middle East and Africa Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Middle East and Africa Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Middle East and Africa Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover Middle East and Africa Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across Turkiye, the UAE, Saudi Arabia, Bahrain, Oman, Egypt, South Africa and Africa, Algeria, Nigeria, Kuwait, and Qatar. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Middle East and Africa Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Middle East and Africa cancer targeted therapy market are:

• In September 2025, the U.S. Food and Drug Administration (FDA) granted approval for a subcutaneous formulation of pembrolizumab (Keytruda), one of the world's leading immune checkpoint inhibitors. Traditionally administered intravenously, pembrolizumab has been a cornerstone of immunotherapy across multiple cancers, including melanoma, lung cancer, and head‑and‑neck cancers.
• In December 2024, Merus—a clinical‑stage oncology company—achieved a major milestone when its bispecific antibody therapy received regulatory approval for the treatment of NRG1 fusion–positive non‑small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. NRG1 gene fusions are rare but aggressive oncogenic drivers that occur across multiple solid tumors, often leaving patients with limited treatment options.